Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.
Bio-Techne
WHERE SCIENCE INTERSECTS INNOVATIONTM
![Western Blot: Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14) [NBP2-50311] - The antigens used were gradient-purified RSN-2 virus in lanes 1 and 4, partial purified PVM (lane 2) and BRS virus (lane 3). First antibodies: Lane 1: RS virus convalescent human sera; Lanes 2, 3 and 4: antibody 4-14. The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies present in the convalescent serum are described in Gimenez et al. (1987).](http://images.novusbio.com/fullsize2/Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14)-Western Blot-NBP2-50311-img0001.jpg "Western Blot: Respiratory Syncytial Virus Subgroup B Antibody (RSV 4-14) [NBP2-50311] - The antigens used were gradient-purified RSN-2 virus in lanes 1 and 4, partial purified PVM (lane 2) and BRS virus (lane 3). First antibodies: Lane 1: RS virus convalescent human sera; Lanes 2, 3 and 4: antibody 4-14. The identity and molecular weight of the protein target of this antibody was validated by including within the immunoblot assay (as a marker) a convalescent serum sample from a RS virus infected patient. The protein specificities of the antibodies present in the convalescent serum are described in Gimenez et al. (1987).")